Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe–America and Asia–Africa from 1998 to 2009
Shigella is becoming an increasing public health problem due to development of multiple antimicrobial resistance, frequently resulting in treatment failure. A systematic review was conducted based on a literature search of computerised databases. Random or fixed-effects models were used, based on th...
Gespeichert in:
| Veröffentlicht in: | International journal of antimicrobial agents 2012-07, Vol.40 (1), p.9-17 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 17 |
|---|---|
| container_issue | 1 |
| container_start_page | 9 |
| container_title | International journal of antimicrobial agents |
| container_volume | 40 |
| creator | Gu, Bing Cao, Yan Pan, Shiyang Zhuang, Ling Yu, Rongbin Peng, Zhihang Qian, Huimin Wei, Yongyue Zhao, Lianying Liu, Genyan Tong, Mingqing |
| description | Shigella is becoming an increasing public health problem due to development of multiple antimicrobial resistance, frequently resulting in treatment failure. A systematic review was conducted based on a literature search of computerised databases. Random or fixed-effects models were used, based on the P-value considering the possibility of heterogeneity between studies, for meta-analysis. Statistical analyses were performed using STATA 10.0. In the area of Asia–Africa, resistance rates to nalidixic acid and ciprofloxacin were 33.6% [95% confidence interval (CI) 21.8–46.6%] and 5.0% (95% CI 2.8–7.8%), respectively, 10.5 and 16.7 times those of Europe–America. Moreover, resistance to nalidixic acid and ciprofloxacin in Asia–Africa progressively increased each year, reaching 64.5% (95% CI 13.8–99.3%) and 29.1% (95% CI 0.9–74.8%), respectively, in 2007–2009, whilst isolates in Europe–America remained at low levels of resistance ( |
| doi_str_mv | 10.1016/j.ijantimicag.2012.02.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1019615266</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924857912000830</els_id><sourcerecordid>1019615266</sourcerecordid><originalsourceid>FETCH-LOGICAL-c552t-d4dc925653aea3075db7d138a0d0682349d03f1c57d64e349cc9136e5b32842b3</originalsourceid><addsrcrecordid>eNqNkkuOEzEQhlsIxISBK4BZIM0mwY-2u71BiqIZQBqJRZi15djViUN3O9idYWbHHTgBV-MkVCfhIVZIliyXvnr4_6soXjI6Y5Sp19tZ2Np-CF1wdj3jlPEZxUPlg2LC6opPK83Ew2JCNS-ntaz0WfEk5y2lTIpSPi7OOC9rIXg5Kb4vYrezKeTYk9iQYQNkl-DWttA7ILb3xG1svw79miTIIQ92jA-R9LYNPtwFR6wL_kiGXYpNG-8wcqi23IQ1tK0lKxi-APTkcp_iDn58_TbvIOHwh7R5DnYMNYdIk2JHmNb12IRTqp8WjxrbZnh2us-Lm6vLj4t30-sPb98v5tdTJyUfpr70TnOppLBgBa2kX1WeidpST1XNRak9FQ1zsvKqBHw6hyIpkCvB65KvxHlxcayLn_i8hzyYLmQ3jt9D3GeDymvFJFcKUX1EXYo5J2jMLoXOpnuERk6ZrfnLITM6ZCgeKjH3-anNftWB_535yxIEXp0Am51tm4SKh_yHU5QxJSrkXhy5xkZj12ihuVliJ4k211xqjsTiSADKdhsgmezC6KsPCdxgfAz_NfCbf6q4NvSItZ_gHvI27hPuAupjMiaY5bh0484xNI_Wgoqf9HPU5Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1019615266</pqid></control><display><type>article</type><title>Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe–America and Asia–Africa from 1998 to 2009</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Gu, Bing ; Cao, Yan ; Pan, Shiyang ; Zhuang, Ling ; Yu, Rongbin ; Peng, Zhihang ; Qian, Huimin ; Wei, Yongyue ; Zhao, Lianying ; Liu, Genyan ; Tong, Mingqing</creator><creatorcontrib>Gu, Bing ; Cao, Yan ; Pan, Shiyang ; Zhuang, Ling ; Yu, Rongbin ; Peng, Zhihang ; Qian, Huimin ; Wei, Yongyue ; Zhao, Lianying ; Liu, Genyan ; Tong, Mingqing</creatorcontrib><description>Shigella is becoming an increasing public health problem due to development of multiple antimicrobial resistance, frequently resulting in treatment failure. A systematic review was conducted based on a literature search of computerised databases. Random or fixed-effects models were used, based on the P-value considering the possibility of heterogeneity between studies, for meta-analysis. Statistical analyses were performed using STATA 10.0. In the area of Asia–Africa, resistance rates to nalidixic acid and ciprofloxacin were 33.6% [95% confidence interval (CI) 21.8–46.6%] and 5.0% (95% CI 2.8–7.8%), respectively, 10.5 and 16.7 times those of Europe–America. Moreover, resistance to nalidixic acid and ciprofloxacin in Asia–Africa progressively increased each year, reaching 64.5% (95% CI 13.8–99.3%) and 29.1% (95% CI 0.9–74.8%), respectively, in 2007–2009, whilst isolates in Europe–America remained at low levels of resistance (<5.0% and <1.0%, respectively). All Shigella flexneri strains showed higher resistance than Shigella sonnei in Europe–America: overall, 3.5% (95% CI 1.4–6.4%) vs. 2.6% (95% CI 1.0–5.0%) resistant to nalidixic acid and 1.0% (95% CI 0.3–2.2%) vs. 0.1% (95% CI 0.0–0.3%) resistant to ciprofloxacin. In Asia–Africa, a similar trend was found for ciprofloxacin [3.0% (95% CI 1.4–5.3%) vs. 0.5% (95% CI 0.2–0.8%)], whereas the trend was reversed for nalidixic acid [32.6% (95% CI 14.5–53.9%) vs. 44.3% (95% CI 26.9–62.5%). In conclusion, quinolone resistance in Shigella has increased at an alarming speed, reinforcing the importance of continuous monitoring of antimicrobial resistance in Shigella.</description><identifier>ISSN: 0924-8579</identifier><identifier>EISSN: 1872-7913</identifier><identifier>DOI: 10.1016/j.ijantimicag.2012.02.005</identifier><identifier>PMID: 22483324</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Africa - epidemiology ; Americas - epidemiology ; Anti-Bacterial Agents - pharmacology ; antibiotic resistance ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Asia - epidemiology ; Biological and medical sciences ; Ciprofloxacin ; Ciprofloxacin - pharmacology ; confidence interval ; Drug Resistance, Bacterial ; Dysentery, Bacillary - epidemiology ; Dysentery, Bacillary - microbiology ; Europe - epidemiology ; Humans ; Infectious Disease ; Medical sciences ; Meta-analysis ; monitoring ; Nalidixic acid ; Nalidixic Acid - pharmacology ; Pharmacology. Drug treatments ; Prevalence ; public health ; Resistance ; Shigella flexneri ; Shigella flexneri - drug effects ; Shigella flexneri - isolation & purification ; Shigella sonnei ; Shigella sonnei - drug effects ; Shigella sonnei - isolation & purification ; statistical analysis ; systematic review</subject><ispartof>International journal of antimicrobial agents, 2012-07, Vol.40 (1), p.9-17</ispartof><rights>Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2012 Elsevier B.V. and the International Society of Chemotherapy</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c552t-d4dc925653aea3075db7d138a0d0682349d03f1c57d64e349cc9136e5b32842b3</citedby><cites>FETCH-LOGICAL-c552t-d4dc925653aea3075db7d138a0d0682349d03f1c57d64e349cc9136e5b32842b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijantimicag.2012.02.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26011637$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22483324$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gu, Bing</creatorcontrib><creatorcontrib>Cao, Yan</creatorcontrib><creatorcontrib>Pan, Shiyang</creatorcontrib><creatorcontrib>Zhuang, Ling</creatorcontrib><creatorcontrib>Yu, Rongbin</creatorcontrib><creatorcontrib>Peng, Zhihang</creatorcontrib><creatorcontrib>Qian, Huimin</creatorcontrib><creatorcontrib>Wei, Yongyue</creatorcontrib><creatorcontrib>Zhao, Lianying</creatorcontrib><creatorcontrib>Liu, Genyan</creatorcontrib><creatorcontrib>Tong, Mingqing</creatorcontrib><title>Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe–America and Asia–Africa from 1998 to 2009</title><title>International journal of antimicrobial agents</title><addtitle>Int J Antimicrob Agents</addtitle><description>Shigella is becoming an increasing public health problem due to development of multiple antimicrobial resistance, frequently resulting in treatment failure. A systematic review was conducted based on a literature search of computerised databases. Random or fixed-effects models were used, based on the P-value considering the possibility of heterogeneity between studies, for meta-analysis. Statistical analyses were performed using STATA 10.0. In the area of Asia–Africa, resistance rates to nalidixic acid and ciprofloxacin were 33.6% [95% confidence interval (CI) 21.8–46.6%] and 5.0% (95% CI 2.8–7.8%), respectively, 10.5 and 16.7 times those of Europe–America. Moreover, resistance to nalidixic acid and ciprofloxacin in Asia–Africa progressively increased each year, reaching 64.5% (95% CI 13.8–99.3%) and 29.1% (95% CI 0.9–74.8%), respectively, in 2007–2009, whilst isolates in Europe–America remained at low levels of resistance (<5.0% and <1.0%, respectively). All Shigella flexneri strains showed higher resistance than Shigella sonnei in Europe–America: overall, 3.5% (95% CI 1.4–6.4%) vs. 2.6% (95% CI 1.0–5.0%) resistant to nalidixic acid and 1.0% (95% CI 0.3–2.2%) vs. 0.1% (95% CI 0.0–0.3%) resistant to ciprofloxacin. In Asia–Africa, a similar trend was found for ciprofloxacin [3.0% (95% CI 1.4–5.3%) vs. 0.5% (95% CI 0.2–0.8%)], whereas the trend was reversed for nalidixic acid [32.6% (95% CI 14.5–53.9%) vs. 44.3% (95% CI 26.9–62.5%). In conclusion, quinolone resistance in Shigella has increased at an alarming speed, reinforcing the importance of continuous monitoring of antimicrobial resistance in Shigella.</description><subject>Africa - epidemiology</subject><subject>Americas - epidemiology</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>antibiotic resistance</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Asia - epidemiology</subject><subject>Biological and medical sciences</subject><subject>Ciprofloxacin</subject><subject>Ciprofloxacin - pharmacology</subject><subject>confidence interval</subject><subject>Drug Resistance, Bacterial</subject><subject>Dysentery, Bacillary - epidemiology</subject><subject>Dysentery, Bacillary - microbiology</subject><subject>Europe - epidemiology</subject><subject>Humans</subject><subject>Infectious Disease</subject><subject>Medical sciences</subject><subject>Meta-analysis</subject><subject>monitoring</subject><subject>Nalidixic acid</subject><subject>Nalidixic Acid - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prevalence</subject><subject>public health</subject><subject>Resistance</subject><subject>Shigella flexneri</subject><subject>Shigella flexneri - drug effects</subject><subject>Shigella flexneri - isolation & purification</subject><subject>Shigella sonnei</subject><subject>Shigella sonnei - drug effects</subject><subject>Shigella sonnei - isolation & purification</subject><subject>statistical analysis</subject><subject>systematic review</subject><issn>0924-8579</issn><issn>1872-7913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkkuOEzEQhlsIxISBK4BZIM0mwY-2u71BiqIZQBqJRZi15djViUN3O9idYWbHHTgBV-MkVCfhIVZIliyXvnr4_6soXjI6Y5Sp19tZ2Np-CF1wdj3jlPEZxUPlg2LC6opPK83Ew2JCNS-ntaz0WfEk5y2lTIpSPi7OOC9rIXg5Kb4vYrezKeTYk9iQYQNkl-DWttA7ILb3xG1svw79miTIIQ92jA-R9LYNPtwFR6wL_kiGXYpNG-8wcqi23IQ1tK0lKxi-APTkcp_iDn58_TbvIOHwh7R5DnYMNYdIk2JHmNb12IRTqp8WjxrbZnh2us-Lm6vLj4t30-sPb98v5tdTJyUfpr70TnOppLBgBa2kX1WeidpST1XNRak9FQ1zsvKqBHw6hyIpkCvB65KvxHlxcayLn_i8hzyYLmQ3jt9D3GeDymvFJFcKUX1EXYo5J2jMLoXOpnuERk6ZrfnLITM6ZCgeKjH3-anNftWB_535yxIEXp0Am51tm4SKh_yHU5QxJSrkXhy5xkZj12ihuVliJ4k211xqjsTiSADKdhsgmezC6KsPCdxgfAz_NfCbf6q4NvSItZ_gHvI27hPuAupjMiaY5bh0484xNI_Wgoqf9HPU5Q</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Gu, Bing</creator><creator>Cao, Yan</creator><creator>Pan, Shiyang</creator><creator>Zhuang, Ling</creator><creator>Yu, Rongbin</creator><creator>Peng, Zhihang</creator><creator>Qian, Huimin</creator><creator>Wei, Yongyue</creator><creator>Zhao, Lianying</creator><creator>Liu, Genyan</creator><creator>Tong, Mingqing</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120701</creationdate><title>Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe–America and Asia–Africa from 1998 to 2009</title><author>Gu, Bing ; Cao, Yan ; Pan, Shiyang ; Zhuang, Ling ; Yu, Rongbin ; Peng, Zhihang ; Qian, Huimin ; Wei, Yongyue ; Zhao, Lianying ; Liu, Genyan ; Tong, Mingqing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c552t-d4dc925653aea3075db7d138a0d0682349d03f1c57d64e349cc9136e5b32842b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Africa - epidemiology</topic><topic>Americas - epidemiology</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>antibiotic resistance</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Asia - epidemiology</topic><topic>Biological and medical sciences</topic><topic>Ciprofloxacin</topic><topic>Ciprofloxacin - pharmacology</topic><topic>confidence interval</topic><topic>Drug Resistance, Bacterial</topic><topic>Dysentery, Bacillary - epidemiology</topic><topic>Dysentery, Bacillary - microbiology</topic><topic>Europe - epidemiology</topic><topic>Humans</topic><topic>Infectious Disease</topic><topic>Medical sciences</topic><topic>Meta-analysis</topic><topic>monitoring</topic><topic>Nalidixic acid</topic><topic>Nalidixic Acid - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prevalence</topic><topic>public health</topic><topic>Resistance</topic><topic>Shigella flexneri</topic><topic>Shigella flexneri - drug effects</topic><topic>Shigella flexneri - isolation & purification</topic><topic>Shigella sonnei</topic><topic>Shigella sonnei - drug effects</topic><topic>Shigella sonnei - isolation & purification</topic><topic>statistical analysis</topic><topic>systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gu, Bing</creatorcontrib><creatorcontrib>Cao, Yan</creatorcontrib><creatorcontrib>Pan, Shiyang</creatorcontrib><creatorcontrib>Zhuang, Ling</creatorcontrib><creatorcontrib>Yu, Rongbin</creatorcontrib><creatorcontrib>Peng, Zhihang</creatorcontrib><creatorcontrib>Qian, Huimin</creatorcontrib><creatorcontrib>Wei, Yongyue</creatorcontrib><creatorcontrib>Zhao, Lianying</creatorcontrib><creatorcontrib>Liu, Genyan</creatorcontrib><creatorcontrib>Tong, Mingqing</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of antimicrobial agents</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gu, Bing</au><au>Cao, Yan</au><au>Pan, Shiyang</au><au>Zhuang, Ling</au><au>Yu, Rongbin</au><au>Peng, Zhihang</au><au>Qian, Huimin</au><au>Wei, Yongyue</au><au>Zhao, Lianying</au><au>Liu, Genyan</au><au>Tong, Mingqing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe–America and Asia–Africa from 1998 to 2009</atitle><jtitle>International journal of antimicrobial agents</jtitle><addtitle>Int J Antimicrob Agents</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>40</volume><issue>1</issue><spage>9</spage><epage>17</epage><pages>9-17</pages><issn>0924-8579</issn><eissn>1872-7913</eissn><abstract>Shigella is becoming an increasing public health problem due to development of multiple antimicrobial resistance, frequently resulting in treatment failure. A systematic review was conducted based on a literature search of computerised databases. Random or fixed-effects models were used, based on the P-value considering the possibility of heterogeneity between studies, for meta-analysis. Statistical analyses were performed using STATA 10.0. In the area of Asia–Africa, resistance rates to nalidixic acid and ciprofloxacin were 33.6% [95% confidence interval (CI) 21.8–46.6%] and 5.0% (95% CI 2.8–7.8%), respectively, 10.5 and 16.7 times those of Europe–America. Moreover, resistance to nalidixic acid and ciprofloxacin in Asia–Africa progressively increased each year, reaching 64.5% (95% CI 13.8–99.3%) and 29.1% (95% CI 0.9–74.8%), respectively, in 2007–2009, whilst isolates in Europe–America remained at low levels of resistance (<5.0% and <1.0%, respectively). All Shigella flexneri strains showed higher resistance than Shigella sonnei in Europe–America: overall, 3.5% (95% CI 1.4–6.4%) vs. 2.6% (95% CI 1.0–5.0%) resistant to nalidixic acid and 1.0% (95% CI 0.3–2.2%) vs. 0.1% (95% CI 0.0–0.3%) resistant to ciprofloxacin. In Asia–Africa, a similar trend was found for ciprofloxacin [3.0% (95% CI 1.4–5.3%) vs. 0.5% (95% CI 0.2–0.8%)], whereas the trend was reversed for nalidixic acid [32.6% (95% CI 14.5–53.9%) vs. 44.3% (95% CI 26.9–62.5%). In conclusion, quinolone resistance in Shigella has increased at an alarming speed, reinforcing the importance of continuous monitoring of antimicrobial resistance in Shigella.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>22483324</pmid><doi>10.1016/j.ijantimicag.2012.02.005</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-8579 |
| ispartof | International journal of antimicrobial agents, 2012-07, Vol.40 (1), p.9-17 |
| issn | 0924-8579 1872-7913 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1019615266 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Africa - epidemiology Americas - epidemiology Anti-Bacterial Agents - pharmacology antibiotic resistance Antibiotics. Antiinfectious agents. Antiparasitic agents Asia - epidemiology Biological and medical sciences Ciprofloxacin Ciprofloxacin - pharmacology confidence interval Drug Resistance, Bacterial Dysentery, Bacillary - epidemiology Dysentery, Bacillary - microbiology Europe - epidemiology Humans Infectious Disease Medical sciences Meta-analysis monitoring Nalidixic acid Nalidixic Acid - pharmacology Pharmacology. Drug treatments Prevalence public health Resistance Shigella flexneri Shigella flexneri - drug effects Shigella flexneri - isolation & purification Shigella sonnei Shigella sonnei - drug effects Shigella sonnei - isolation & purification statistical analysis systematic review |
| title | Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe–America and Asia–Africa from 1998 to 2009 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A35%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20prevalence%20and%20changing%20resistance%20to%20nalidixic%20acid%20and%20ciprofloxacin%20of%20Shigella%20between%20Europe%E2%80%93America%20and%20Asia%E2%80%93Africa%20from%201998%20to%202009&rft.jtitle=International%20journal%20of%20antimicrobial%20agents&rft.au=Gu,%20Bing&rft.date=2012-07-01&rft.volume=40&rft.issue=1&rft.spage=9&rft.epage=17&rft.pages=9-17&rft.issn=0924-8579&rft.eissn=1872-7913&rft_id=info:doi/10.1016/j.ijantimicag.2012.02.005&rft_dat=%3Cproquest_cross%3E1019615266%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1019615266&rft_id=info:pmid/22483324&rft_els_id=S0924857912000830&rfr_iscdi=true |